Blair William & Co. IL Has $315.72 Million Position in Stryker Co. (NYSE:SYK)

Blair William & Co. IL increased its holdings in shares of Stryker Co. (NYSE:SYK) by 0.1% during the 2nd quarter, HoldingsChannel reports. The firm owned 927,910 shares of the medical technology company’s stock after purchasing an additional 1,332 shares during the period. Stryker comprises approximately 1.0% of Blair William & Co. IL’s holdings, making the stock its 21st largest holding. Blair William & Co. IL’s holdings in Stryker were worth $315,721,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. Global Assets Advisory LLC acquired a new position in shares of Stryker in the first quarter valued at approximately $341,049,000. JPMorgan Chase & Co. boosted its stake in Stryker by 10.4% in the 1st quarter. JPMorgan Chase & Co. now owns 8,651,403 shares of the medical technology company’s stock worth $3,096,078,000 after purchasing an additional 813,311 shares during the period. Price T Rowe Associates Inc. MD increased its holdings in Stryker by 5.4% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 12,541,845 shares of the medical technology company’s stock worth $3,755,782,000 after purchasing an additional 642,178 shares in the last quarter. 1832 Asset Management L.P. raised its stake in shares of Stryker by 146.9% in the 1st quarter. 1832 Asset Management L.P. now owns 878,669 shares of the medical technology company’s stock valued at $314,449,000 after purchasing an additional 522,817 shares during the period. Finally, American Century Companies Inc. lifted its holdings in shares of Stryker by 287.6% in the second quarter. American Century Companies Inc. now owns 505,608 shares of the medical technology company’s stock valued at $172,033,000 after purchasing an additional 375,166 shares in the last quarter. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the company. Truist Financial decreased their price objective on Stryker from $364.00 to $345.00 and set a “hold” rating for the company in a report on Thursday, August 1st. Evercore ISI decreased their price target on shares of Stryker from $370.00 to $365.00 and set an “outperform” rating for the company in a research note on Tuesday, July 2nd. Stifel Nicolaus cut their price objective on shares of Stryker from $375.00 to $365.00 and set a “buy” rating on the stock in a research report on Wednesday, July 31st. The Goldman Sachs Group assumed coverage on shares of Stryker in a research report on Thursday, May 30th. They issued a “neutral” rating and a $372.00 target price for the company. Finally, Needham & Company LLC boosted their price target on shares of Stryker from $392.00 to $393.00 and gave the stock a “buy” rating in a research report on Thursday, August 1st. Five research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $378.58.

Insider Buying and Selling

In other Stryker news, insider Viju Menon sold 600 shares of the company’s stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $355.00, for a total value of $213,000.00. Following the transaction, the insider now directly owns 9,069 shares of the company’s stock, valued at approximately $3,219,495. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other Stryker news, insider Viju Menon sold 600 shares of the business’s stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $355.00, for a total value of $213,000.00. Following the completion of the sale, the insider now owns 9,069 shares of the company’s stock, valued at approximately $3,219,495. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Glenn S. Boehnlein sold 20,000 shares of the firm’s stock in a transaction that occurred on Friday, August 2nd. The stock was sold at an average price of $333.00, for a total transaction of $6,660,000.00. Following the transaction, the chief financial officer now directly owns 2,852 shares in the company, valued at $949,716. The disclosure for this sale can be found here. In the last ninety days, insiders sold 220,068 shares of company stock valued at $71,811,372. Insiders own 5.90% of the company’s stock.

Stryker Trading Down 2.1 %

Shares of Stryker stock opened at $364.00 on Wednesday. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.68 and a quick ratio of 0.95. The business has a fifty day simple moving average of $343.60 and a two-hundred day simple moving average of $342.61. Stryker Co. has a 1 year low of $249.98 and a 1 year high of $374.63. The company has a market capitalization of $138.71 billion, a price-to-earnings ratio of 41.55, a P/E/G ratio of 2.87 and a beta of 0.91.

Stryker (NYSE:SYK) last posted its earnings results on Tuesday, July 30th. The medical technology company reported $2.81 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.79 by $0.02. Stryker had a net margin of 16.12% and a return on equity of 22.89%. The company had revenue of $5.42 billion during the quarter, compared to analysts’ expectations of $5.40 billion. During the same quarter last year, the company posted $2.54 EPS. Stryker’s quarterly revenue was up 8.5% compared to the same quarter last year. Research analysts forecast that Stryker Co. will post 12 EPS for the current year.

Stryker Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, October 31st. Stockholders of record on Monday, September 30th will be paid a dividend of $0.80 per share. The ex-dividend date is Monday, September 30th. This represents a $3.20 dividend on an annualized basis and a dividend yield of 0.88%. Stryker’s dividend payout ratio (DPR) is currently 36.53%.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.